Recent Articles from GlobeNewswire

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26.50, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 exercise price per share for each pre-funded warrant. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $100 million. Assembly Bio has also granted the underwriters a 30-day option to purchase up to an additional 566,040 shares of common stock at the offering price, less underwriting discounts and commissions.

LONDON, May 22, 2026 (GLOBE NEWSWIRE) -- According to Get Golden Visa’s internal data, one in five real estate investments under Greece Golden Visa program is made by families planning for their children’s future education. Once, investors mainly preferred this flexible route for its Schengen mobility and capital appreciation potential; now the landscape indicates that Greece Golden Visa program has become a tool for broader lifestyle and education planning.

SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Concorde International Group Ltd. (NASDAQ: YOOV) (the “Company”), an integrated provider of technology-enabled security solutions, today highlighted its continued recognition in the facilities security industry, reflecting more than a decade of leadership in delivering comprehensive security services through its proprietary operational model.

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU).

SHANGHAI, May 22, 2026 (GLOBE NEWSWIRE) -- Chagee Holdings Limited (NASDAQ: CHA) (“Chagee” or the “Company”), a leading premium tea drinks brand serving healthy and delicious freshly-made tea drinks, today announced that it plans to report its financial results for the first quarter ended March 31, 2026, after the U.S. market closes on May 28, 2026.

No Shareholder Action Required at this Time

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

New physically deliverable 1,000 oz, four-nines silver contract supports price discovery and risk management for global industrial silver markets

– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV –

MAHIA, New Zealand, May 22, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today announced the successful deployment of the latest satellite for Synspective, marking the ninth dedicated mission Rocket Lab has completed for the Japan-based Earth observation constellation. This launch further strengthens one of the most consistent commercial launch partnerships in the small satellite sector and highlights Electron's industry-leading dedicated launch service.

HOUSTON and LONDON, May 22, 2026 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB) today announced it has declared a dividend of $0.69 per share, to be paid to shareholders on June 8, 2026, with an ex-dividend and record date of June 1, 2026.

$612 Million Issuance Backed by Aircraft Receives Strong Investor Reception and Marks Strategic Entry into ABS Capital Markets

BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading AI-driven agricultural digital service company in China, today announced that its WolaiCai AI Agent has been fully deployed across all platforms. The system now consumes over 200 million tokens daily, with agricultural AI-related products generating more than RMB20,000 (approximately US$3,000) in daily revenue. As AI enhances user service efficiency, the Company’s agricultural AI strategy continues to deliver growing commercial returns, demonstrating both industrial and commercial value.

GOUVERNEUR, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Titan Mining Corporation (“Titan” or the “Company”), an existing zinc concentrate producer in upstate New York and the only U.S. end-to-end producer of natural flake graphite, is pleased to announce the appointment of Mr. Matthew Melnyk, CPG, M.Sc., as Vice President, Geology and Exploration, and Ms. Ashley Kates, CPA, CA, as Interim Chief Financial Officer of the Company, effective May 22, 2026, following Mr. Kevin Hart’s decision to resign for personal reasons.

LISHUI, China, May 22, 2026 (GLOBE NEWSWIRE) -- Lixiang Education Holding Co., Ltd. (the “Company” or NASDAQ: LXEH), a prestigious private education service provider in China, today announced that on May 21, 2026, it received a letter from the Listing Qualification Department of Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 10 consecutive business days, from May 7, 2026 to May 20, 2026, the closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and this matter is now closed.

FREMONT, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- The consolidation wave Litera flagged at the end of last year is here. Litera’s late-2025 outlook called it: 2026 would push the U.S. legal tech market away from scattered point solutions and toward unified platforms, with buyers actively trimming the number of vendors they work with. By mid-2026, that prediction is reflected in buyer behavior. Corporate legal departments and law firms are reducing their active vendor counts and routing more work through fewer, more integrated providers. Southeast Asian (S.E.A.) legal-tech founders entering the U.S. market now face a narrower set of buyer expectations than they did twelve months ago. Dmitry Shubov, founder of Dmitry Shubov Consulting, is weighing in on what this shift means for Southeast Asian (S.E.A.) legal-tech founders, who now face a narrower set of U.S. buyer expectations than they did twelve months ago.What U.S. acquirers and corporate buyers are prioritizing right now:

Transaction in Own Shares

MONACO, May 22, 2026 (GLOBE NEWSWIRE) -- The Yacht Club de Monaco unveiled its new Hemingway Cigar Lounge, a completely redesigned area in the heart of the Club for its members and their guests. The intimate setting combines all the elegance, discretion and culture, for which YCM is renowned, in a timeless fashion where artisanal craftsmanship takes centre stage.

MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart. In addition, four trial in progress poster presentations will illustrate advancement of the Company’s ongoing pivotal trials and novel-novel combination trials, including antibody-drug conjugates (“ADC”).

AREZZO, Italy, May 22, 2026 (GLOBE NEWSWIRE) -- Italpreziosi S.p.A. is pleased to announce its official inclusion in the LBMA Silver Good Delivery List, one of the most prestigious international standards in the precious metals industry.

Geneva, Switzerland, May 22, 2026 (GLOBE NEWSWIRE) -- Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action.

MIAMI, May 22, 2026 (GLOBE NEWSWIRE) -- ARKAY is proud to announce the launch of its new 200 ml Mocktail Tetra Pack Collection, a convenient, ready-to-drink line created for today’s fast-moving consumers who are looking for great taste, portability, and alcohol-free options.

The largest cycling event in Slovenian history will bring 800 riders from 50+ countries to the roads of Slovenia — including Slovenian cycling stars Tadej Pogačar and Primož Roglič

Schiphol, May 22, 2026 - Aegon today announces that Jennifer Palmieri will join Aegon as Chief Human Resources Officer and member of Aegon’s Executive Committee, effective June 29, 2026. She will succeed Holly Waters who will retire as of June 1, 2026. 

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026

 VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance.

BEIJING, May 21, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time.

NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions.

Global Down Syndrome Foundation Honored Sen. Shelley Moore Capito and Rep. Paul Tonko at Event that Featured Award-Winning Multiplatinum Artist Rachel Platten and Inclusive Dance Team

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance, Inc. (Nasdaq: AGAE) (the “Company” or “AIFA”) today provided an update regarding the previously received notice from the Listing Qualifications Department of The Nasdaq Stock Market.

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”).

ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO’s official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company’s three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575); and MDM2-p53 inhibitor alrizomadlin (APG-115).

Award marks Rocket Lab's first satellite production program for geostationary orbit and continues a Space Systems Command program for development and delivery on orbit of two Heimdall prototype payloads by Rocket Lab Optical Systems

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE:PHR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ:Z) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of York Space Systems Inc. (“York Space Systems” or the “Company”) (NYSE:YSS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Claritev Corporation (“Claritev” or the “Company”) (NYSE:CTEV) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Calix, Inc. (“Calix” or the “Company”) (NYSE:CALX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

Fresno, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Mason Street Wealth Management, a leading financial services firm specializing in retirement planning, highlights its innovative vision-first financial strategy, designed to help individuals approaching retirement turn their ideal future into a structured, actionable plan. By prioritizing personal goals before financial products, the firm is redefining how retirement planning is approached in today’s evolving financial landscape.

A multi-year partnership centered on “Ultimate Connection” through music, technology, and unforgettable live experiences

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --

Greenville, NC, May 21, 2026 (GLOBE NEWSWIRE) -- Carolina Financial Services Group, a Registered Investment Advisor firm with more than 30 years of experience in the Greenville and eastern North Carolina region as well as in the entire East Coast, is addressing the critical need for retirees to mitigate taxation and healthcare costs through a specialized, tech-enabled planning process.

130 first-time exhibitors signal explosive growth across sports, gaming, and food & beverage, while industry heavyweights converged to shape the next wave of consumer products

From immersive audio to smart home security, Anker Innovations' portfolio debuts breakthrough technology at annual showcase

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (NASDAQ:ATEC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased POET Technologies Inc. (“POET” or the “Company”) (NASDAQ:POET) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP is delighted to announce yet another closing in Uzbekistan having secured funding from OeEB, the Development Bank of Austria, to support Asia Alliance Bank.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Claritev (CTEV) To Contact Him Directly To Discuss Their Options

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson’s disease. Results from the study show that BIIB122 did not slow the progression of Parkinson’s disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson’s disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.

Project Gravity provides advertisers and data owners with a neutral platform that onboards and activates their first party data across Google DV360, The Trade Desk, Meta, TikTok, Amazon, Magnite, and many other Samba partners

LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In York Space Systems (YSS) To Contact Him Directly To Discuss Their Options

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Black Rock (BRCB) To Contact Him Directly To Discuss Their Options

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Commvault (CVLT) To Contact Him Directly To Discuss Their Options

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sportradar (SRAD) To Contact Him Directly To Discuss Their Options

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology® (ASCO®) Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT.

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of March 31, 2026, of $20.9 million. Net asset value per share increased to $1.50 as of March 31, 2026, from $1.19 as of December 31, 2025. Comparative data is summarized below (in thousands, except per share amounts):  

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --

SAN FRANCISCO and SHENZHEN, China and ZHANGJIAJIE, China, May 21, 2026 (GLOBE NEWSWIRE) -- Hitch Open World AI Championships and Whale Dynamic today announced that their strategic partnership has entered full-scale delivery. Whale Dynamic will provide all Hitch Open competing teams with a centimeter-accurate 3D high-definition (HD) map covering the entire 10.77-kilometer Tianmen Mountain course—featuring 1,100 meters of elevation change and 99 consecutive hairpin turns—as the unified localization baseline for the Hitch Open World AI Racing Championships 2026, scheduled for June 25–26 in Zhangjiajie, China.

ACHESON, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA/NYSE:NOA) today announced the results of its Annual and Special Meeting of Shareholders held on May 20, 2026.  Shareholders elected directors, approved the appointment of KPMG LLP as the independent auditors of the Company, approved a non-binding advisory vote regarding the Company’s approach to executive compensation and ratified an Advance Notice Bylaw.  The following are the results of the votes held at the meeting:

MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon’s pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005.

Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile